Clinical trial ACTION-1
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), welldifferentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior treatment with 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1 / RYZ101-301)
| Cancers | |
|---|---|
| Organ | Neuroendocrine tumours |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/3 |
| Academic trial | Non |
| Sponsor | RayzeBio Inc. |
| EudraCT Identifier | 2022-000507-12 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05477576 |
| Last update |